ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study

Charlotte Rose Lemech, Ganessan Kichenadasse, Jens-Peter Marschner, Konstantinos Alevizopoulos, Marit Otterlei, Michael Millward

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Fingerprint

Dive into the research topics of 'ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science